- Home
- TPST
TPST
Tempest Therapeutics Inc.
as 04-29-2025 4:00pm EST
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 86.5K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -19.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.36 - $49.27 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tempest Therapeutics Inc. News
TPST Breaking Stock News: Dive into TPST Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire
9 days ago
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
GlobeNewswire
20 days ago
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
GlobeNewswire
a month ago
Tempest Reports Year End 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
2 months ago
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
GlobeNewswire
3 months ago
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
GlobeNewswire
3 months ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Compare TPST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TPST Tempest Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.